Spatial analysis of the glioblastoma proteome reveals specific molecular signatures and markers of survival.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
04 11 2022
04 11 2022
Historique:
received:
19
04
2022
accepted:
18
10
2022
pubmed:
6
11
2022
medline:
9
11
2022
entrez:
5
11
2022
Statut:
epublish
Résumé
Molecular heterogeneity is a key feature of glioblastoma that impedes patient stratification and leads to large discrepancies in mean patient survival. Here, we analyze a cohort of 96 glioblastoma patients with survival ranging from a few months to over 4 years. 46 tumors are analyzed by mass spectrometry-based spatially-resolved proteomics guided by mass spectrometry imaging. Integration of protein expression and clinical information highlights three molecular groups associated with immune, neurogenesis, and tumorigenesis signatures with high intra-tumoral heterogeneity. Furthermore, a set of proteins originating from reference and alternative ORFs is found to be statistically significant based on patient survival times. Among these proteins, a 5-protein signature is associated with survival. The expression of these 5 proteins is validated by immunofluorescence on an additional cohort of 50 patients. Overall, our work characterizes distinct molecular regions within glioblastoma tissues based on protein expression, which may help guide glioblastoma prognosis and improve current glioblastoma classification.
Identifiants
pubmed: 36333286
doi: 10.1038/s41467-022-34208-6
pii: 10.1038/s41467-022-34208-6
pmc: PMC9636229
doi:
Substances chimiques
Proteome
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6665Informations de copyright
© 2022. The Author(s).
Références
Sci Rep. 2016 May 18;6:25919
pubmed: 27189490
PLoS Comput Biol. 2017 Sep 28;13(9):e1005739
pubmed: 28957313
Cancer Cell. 2021 Apr 12;39(4):509-528.e20
pubmed: 33577785
Cancers (Basel). 2019 Mar 01;11(3):
pubmed: 30832246
Brain Pathol. 2010 Jul;20(4):691-703
pubmed: 20175778
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2040-4
pubmed: 16103458
Proteomics. 2014 Oct;14(20):2249-60
pubmed: 25056804
Nat Commun. 2022 Jan 10;13(1):116
pubmed: 35013227
F1000Prime Rep. 2014 Jun 02;6:46
pubmed: 24991423
J Extracell Vesicles. 2017 May 26;6(1):1321455
pubmed: 28717418
Neuro Oncol. 2011 Sep;13(9):926-42
pubmed: 21852429
J Proteomics. 2013 Feb 21;79:200-18
pubmed: 23291530
Sci Rep. 2017 Apr 4;7(1):603
pubmed: 28377615
Ann Neurol. 2002 Mar;51(3):393-405
pubmed: 11891838
Angew Chem Int Ed Engl. 2009;48(44):8240-2
pubmed: 19746375
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Mol Cancer Ther. 2019 Jun;18(6):1092-1103
pubmed: 30962321
J Proteome Res. 2010 Dec 3;9(12):6535-46
pubmed: 20954702
iScience. 2020 May 22;23(5):101045
pubmed: 32334413
Nucleic Acids Res. 2020 Aug 20;48(14):7864-7882
pubmed: 32324228
J Integr Bioinform. 2012 Mar 21;9(1):189
pubmed: 22433312
Cell Rep. 2021 Mar 2;34(9):108787
pubmed: 33657365
Ann Oncol. 2018 Jun 1;29(6):1431-1436
pubmed: 29617713
Neuro Oncol. 2014 Nov;16(11):1469-77
pubmed: 25155358
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):566-575
pubmed: 17255279
J Clin Invest. 2019 Mar 11;129(4):1671-1683
pubmed: 30855281
Trends Biochem Sci. 2021 Mar;46(3):239-250
pubmed: 33246829
Anal Chem. 2006 Feb 1;78(3):809-19
pubmed: 16448055
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186
pubmed: 33293629
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Hum Pathol. 2012 Aug;43(8):1289-99
pubmed: 22304788
Mol Oncol. 2019 Dec;13(12):2588-2603
pubmed: 31487431
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Nat Protoc. 2019 Nov;14(11):3162-3182
pubmed: 31597965
J Proteome Res. 2011 Apr 1;10(4):1794-805
pubmed: 21254760
Mol Cell Proteomics. 2018 Dec;17(12):2402-2411
pubmed: 30181344
Genome Biol. 2019 Sep 2;20(1):185
pubmed: 31477170
Nucleic Acids Res. 2021 Jan 8;49(D1):D380-D388
pubmed: 33179748
Cancer Cell. 2012 Oct 16;22(4):425-37
pubmed: 23079654
Oncoimmunology. 2018 Oct 16;8(1):e1514921
pubmed: 30546954
Curr Res Transl Med. 2019 Nov;67(4):129-133
pubmed: 31501045
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
Br J Cancer. 2002 Sep 23;87(7):746-50
pubmed: 12232758
Oncol Rep. 2019 Feb;41(2):1359-1366
pubmed: 30535461
Proteomics. 2015 Apr;15(8):1453-6
pubmed: 25644178
Neurology. 2016 Jun 14;86(24):2226-34
pubmed: 27225222
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
Front Oncol. 2018 Apr 20;8:123
pubmed: 29732319
J Neurol Surg A Cent Eur Neurosurg. 2018 Nov;79(6):471-478
pubmed: 29959764
Cancer Res. 2015 Sep 1;75(17):3519-28
pubmed: 26122847
J Proteome Res. 2007 Nov;6(11):4127-34
pubmed: 17939699
Mol Cell Proteomics. 2019 Oct;18(10):2029-2043
pubmed: 31353322
Anal Chem. 2006 Oct 15;78(20):7145-53
pubmed: 17037914
Cell. 2019 Aug 8;178(4):835-849.e21
pubmed: 31327527
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Sci Rep. 2018 Oct 8;8(1):14965
pubmed: 30297697
In Vivo. 2017 Mar-Apr;31(2):221-229
pubmed: 28358704
PLoS One. 2013 Aug 12;8(8):e70698
pubmed: 23950983
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Oncotarget. 2017 Jul 4;8(27):44141-44158
pubmed: 28498803
Acta Neuropathol. 2020 Mar;139(3):603-608
pubmed: 31996992
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
Front Cell Dev Biol. 2021 Dec 23;9:703583
pubmed: 35004666
J Neurooncol. 2001 May;52(3):253-61
pubmed: 11519856
Cancer Res. 2003 Jun 1;63(11):2933-9
pubmed: 12782600
Sci Transl Med. 2013 Jul 17;5(194):194ra93
pubmed: 23863833
Cancer Cell. 2018 Nov 12;34(5):840-851.e4
pubmed: 30344004
Proteomics. 2018 May;18(10):e1700058
pubmed: 28627015
Proteomics. 2016 Jun;16(11-12):1622-32
pubmed: 26929135
N Engl J Med. 2014 Feb 20;370(8):709-22
pubmed: 24552318
Neuro Oncol. 2021 Oct 5;23(12 Suppl 2):iii1-iii105
pubmed: 34608945